UP-62 Evaluating the acceptability of an electronic patient decision-aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia
Thursday June 27, 2019 from

David Bouhadana, Canada

McGill University


Evaluating the acceptability of an electronic patient decision-aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia

David Bouhadana1, David-Dan Nguyen1, Brendan Raizenne3, Joe Schwarcz1, Harvey Gordon2, Bilal Chughtai8, Dean S. Elterman2, Luke T. Lavallee4, Paul R. Martin5, Kristen McAlpine2, Ryan F. Paterson6, Hassan Razvi7, Kevin C. Zorn3, Naeem Bhojani3.

1Faculty of Medicine, McGill University, Montreal, QC, Canada; 2Division of Urology, Dept. of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada; 3Department of Urology, Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada; 4Department of Surgery, Division of Urology, University of Ottawa, Ottawa, ON, Canada; 5Department of Urology, Bluewater Health, Sarnia, ON, Canada; 6Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; 7Division of Urology, Department of Surgery, The University of Western Ontario, London, ON, Canada; 8Department of Urology, NY-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, United States

Canadian Urology Association - We thank the CUA for endorsing the development of this PtDA. Ian Langleben and Stella-Kim Nguyen for the programming and designing of this PtDA.

With the help of a steering committee that included patient advocates, and both methodological and clinical experts, an electronic patient decision aid (PtDA) that includes all BPH guideline-approved surgical modalities was developed. The goal of this study is to assess the acceptability of the PtDA within former BPH surgery patients and urologists that treat BPH surgically.

The Ottawa Decision Support Framework was used to develop a PtDA that addresses monopolar transurethral resection of the prostate (TURP), bipolar TURP, GreenLight photovaporization, enucleation, Rezum, Urolift, Aquablation, open retropubic prostatectomy, and robotic retropubic prostatectomy. The PtDA was divided into 3 sections according to prostate volumes. 11 urologists that regularly treat BPH surgically were recruited to review the full PtDA and to complete alpha testing. Alpha-testing was achieved through a survey developed from a validated acceptability scoring system.

For all sections of the PtDA, the urologists agreed that the language used was easy to follow, that the amount of information provided was about right, that the length of the PtDA was appropriate, and that the outcomes reported were correct (Table 1). All 11 urologist participants (100%) found that the description of the treatments within the moderate to large prostate section of the PtDA was well balanced. For both the small to moderate, and large prostate sections, 91% (10/11) of participants found treatment descriptions were well balanced (Table 2). Overall, urologists agreed that they anticipate using this PtDA once complete and that they are satisfied with the overall quality of the PtDA. Alpha-testing within the patient population is currently underway with finalized results expected before June. Preliminary results for the patient population are listed in Table 3.

Our PtDA was found to be acceptable amongst clinicians. These results demonstrate that the majority of the clinician participants were satisfied with the quality of this PtDA and plan to incorporate this tool in their practice.

© 2023 CUA 74th Annual Meeting